Identification of Q-Markers from Hedan Tablet by Employing "spider-web" Mode and Taking Compounds' Hepatotoxicity into Account
Overview
Authors
Affiliations
Objective: Due to the complicated compounds and the synergistic effect of multi-compounds, the quality control and assessment of Chinese materia medica (CMM) encounters a great challenge about how to identify the key compounds, which are directly correlated with its efficacy and safety. On the guidance of study on quality marker (Q-Marker), identification of Q-Markers was performed from Hedan Tablet (HDT) by the aid of the "spider-web" mode and hepatotoxicity evaluation derived from our previous researches and literatures.
Methods: By the established ultra performance liquid chromatography with photodiode array detector (UPLC-PDA) method, online UPLC-DPPH· and offline antioxidant assay, 21 candidate compounds of HDT were systematically investigated and comprehensively evaluated by the "spider-web" mode for them properties of Q-Marker based on "content-stability-activity". In addition, the Q-Markers related with hepatotoxicity based on our previous researches and literatures were identified.
Results: Salvianolic acid B (SaB), quercetin-3--glucuronide (Qug), isoquercitrin (IQ) and hyperoside (Hyp) were adopted as the preferable Q-Markers of HDT according to the shaded area (A) of tested compounds in "spider-web" mode. Psoralen (Ps), isopsoralen (IP), psoralenoside (PO) and isopsoralenoside (IPO) were also strongly recommended as Q-Markers closely related with safety by considering hepatotoxicity of the accumulated Ps and IP and conversion between glycoside (PO and IPO) and aglycone (Ps and IP).
Conclusion: This study provided scientific evidence for quality control and assessment of HDT, and also provided a meaningful reference for application of Q-Markers in CMM.
Zhi H, Fu H, Zhang Y, Fan N, Zhao C, Li Y Front Immunol. 2024; 15:1510628.
PMID: 39737190 PMC: 11683013. DOI: 10.3389/fimmu.2024.1510628.
Yang X, Sima Y, Luo X, Li Y, He M J Pharm Anal. 2024; 14(4):100936.
PMID: 38655399 PMC: 11036100. DOI: 10.1016/j.jpha.2024.01.004.
Zhou E, Shen Q, Hou Y Front Pharmacol. 2024; 15:1181183.
PMID: 38464717 PMC: 10921893. DOI: 10.3389/fphar.2024.1181183.